Cartesian Therapeutics (NASDAQ:RNAC) Earns Buy Rating from H

HC Wainwright restated their buy rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a report published on Thursday morning, Benzinga reports. HC Wainwright currently has a $54.00 price objective on the stock. Other equities research analysts also recently issued reports about the stock. SVB Leerink assumed coverage on shares of Cartesian Therapeutics […]

Related Keywords

United States , American , Timothya Springer , Leerink Partnrs , Needham Company , Artal Group , Cartesian Therapeutics Inc , Cartesian Therapeutics Company Profile , Vanguard Group Inc , American International Group Inc , Delphi Financial Group Inc , Cartesian Therapeutics , Free Report , Therapeutics Stock Down , Get Free Report , Director Timothy , Financial Group , Financial Markets , American International Group , Cartesian Therapeutics Daily ,